Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 26,313 Shares of Stock

Key Points

• Tempus AI CFO James William Rogers sold 26,313 shares at an average price of $60, generating $1.58 million. The sale was made under a pre-arranged Rule 10b5-1 plan to cover tax obligations tied to vested equity awards, leaving him with 106,024 shares.
• Tempus AI shares rose 8.8% to $66.65 during Thursday trading, with volume substantially above average. The stock has a market capitalization of about $12.03 billion and trades well below its 52-week high of $104.32.
• The company recently reported better-than-expected quarterly results, including a loss of $0.04 per share versus expectations of $0.14 and revenue of $382.49 million, up 21.6% year over year. Analysts maintain an overall “Hold” rating with an average price target of $65.69.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CFO James William Rogers sold 26,313 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer owned 106,024 shares in the company, valued at approximately $6,361,440. This represents a 19.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Tuesday, August 18th, James William Rogers sold 22,529 shares of Tempus AI stock. The shares were sold at an average price of $49.61, for a total transaction of $1,117,663.69.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00.

Tempus AI Stock Up 8.8%

NASDAQ TEM traded up $5.40 during mid-day trading on Thursday, reaching $66.65. The stock had a trading volume of 20,103,049 shares, compared to its average volume of 5,600,288. The stock has a market cap of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company has a fifty day moving average price of $52.44 and a 200 day moving average price of $51.21.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the business posted ($0.22) EPS. The company's revenue was up 21.6% compared to the same quarter last year. On average, research analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on TEM. Piper Sandler dropped their price objective on Tempus AI from $58.00 to $56.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 4th. Stifel Nicolaus decreased their target price on Tempus AI from $60.00 to $50.00 and set a "hold" rating for the company in a research report on Monday, August 3rd. Freedom Capital upgraded shares of Tempus AI to a "hold" rating in a research note on Tuesday, June 30th. TD Cowen reaffirmed a "buy" rating on shares of Tempus AI in a report on Wednesday, July 15th. Finally, Wall Street Zen raised shares of Tempus AI from a "sell" rating to a "hold" rating in a report on Saturday, July 25th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $65.69.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC bought a new position in shares of Tempus AI during the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI in the fourth quarter worth $27,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Tempus AI in the third quarter worth $38,000. Whittier Trust Co. grew its holdings in shares of Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after acquiring an additional 570 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Tempus AI by 88.8% during the second quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company's stock valued at $44,000 after acquiring an additional 325 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source